icon

abNEX™ MTB Kit

Targeted NGS workflow for tuberculosis detection, MTBC/NTM review, drug-resistance gene analysis, and co-infection pathogen differentiation.

Targeted MTB NGS

abNEX MTB Kit

Targeted NGS - abNEX

The abNEX™ MTB Panel Kit is positioned for targeted NGS-based tuberculosis workflows that need MTBC detection, non-tuberculous mycobacteria coverage, drug-resistance mutation review, and differentiation from co-infection pathogens in respiratory sample workflows.

MTBC99 NTM34 DR genes48 co-infection pathogens17 anti-TB drugs3 anti-NTM drugs
abNEX MTB Kit targeted NGS workflow

Key Details

  • Supports detection of Mycobacterium tuberculosis complex (MTBC) and 99 non-tuberculous mycobacteria (NTM).
  • Covers 34 drug-resistance genes associated with first-line anti-TB drugs, second-line anti-TB drugs, and anti-NTM drugs.
  • Reported lower limit of detection is 50 copies/mL, supporting low-concentration MTB/NTM investigations.
  • Detects more than 340 anti-TB drug-associated mutations and 19 anti-NTM drug-associated mutations.
  • Co-pathogen coverage includes 26 bacteria, 10 fungi, 5 DNA viruses, 4 atypical pathogens, and 3 parasites.
  • Sample compatibility is focused on respiratory samples such as sputum and BAL, with additional workflow references for BALF, pleural fluid, ascites fluid, and CSF.

Workflow Snapshot

DR genes34
Co-infection pathogens48
MycobacteriaMTBC + 99 NTM
Drug scope17 anti-TB + 3 anti-NTM drugs
LOD50 copies/mL reported
Run context10.5-hour MTB panel workflow reference

Product Positioning

AreaDetails
Drug-resistance scope5 first-line anti-TB drugs associated with 8 resistance genes, 12 second-line anti-TB drugs associated with 22 resistance genes, and 3 anti-NTM drugs associated with 4 resistance genes.
Drugs listedRifampicin, pyrazinamide, isoniazid, ethambutol, streptomycin, levofloxacin, moxifloxacin, amikacin, capreomycin, kanamycin, ethionamide, sodium aminosalicylate, cycloserine, clofazimine, bedaquiline, linezolid, and delamanid.
Resistance genes listedrpoB, katG, inhA, pncA, embB, rpsL, rrs, gid, gyrA, gyrB, cycA, ald, tlyA, eis, folC, ethA, thyA, alr, Rv0678, atpE, ddn, rplC, and ribD.
Co-pathogen breakdown48 pathogens for differentiation from tuberculosis or co-infection review: 26 bacteria, 10 fungi, 5 DNA viruses, 4 atypical pathogens, and 3 parasites.
Ordering referencePart number 302212, abNEX MTB Panel Kit, 48 reactions per kit.

Implementation Note

Use this page for MTB sequencing requests where MTBC/NTM coverage, drug-resistance mutations, and co-infection pathogen differentiation are all part of the discussion.

Confirm respiratory sample type, extraction workflow, sequencing setup, interpretation needs, and local regulatory use before implementation.

Request Information

abNEX Workflow

20 mins

Sample pre-treatment

abPrep™ 6 / abPrep™ 24 with abGenix™ Sample Diluent.

30 mins

Nucleic acid extraction / detection prep

abGenix™ Automated DNA & RNA Extraction System with abGenix™ Universal Extraction Kit.

4 hours

Library preparation

abNEX™ MTB Panel Kit using HyPA primer-based amplification.

4 hours

Sequencing

abSEQ™ Genetic Sequencer with abSEQ™ Sequencing Set.

30 mins

Bioinformatics analysis

abTRON™ Intelligent Center.

Ordering Information

800580abPrep™ 61 unit
800581abPrep™ 241 unit
800800abGenix™ Automated DNA & RNA Extraction System1 unit
801001abSEQ™ Genetic Sequencer1 unit
801021abTRON™ Intelligent Center1 unit
800970abGenix™ Sample Diluent48 rxns/kit
800971abGenix™ Universal Extraction Kit48 rxns/kit
302211abNEX™ Pan-Infection Kit48 rxns/kit
302212abNEX™ MTB Panel Kit48 rxns/kit
302011abSEQ™ Sequencing Set SE10048 rxns/kit

MTB Method Comparison Notes

MethodSample typesCoverage summaryTimePerformance notes
abNEX MTB Panel KitBALF, pleural fluid, ascites fluid, sputum, CSFMTBC, NTM, drug-resistance genes, co-infections; includes the drugs and resistance genes listed above.10.5 hours95.45% sensitivity and 95.65% specificity in the comparison reference.
Brand C Kit 1Sputum and respiratory tract samplesMTBC with rifampicin resistance via rpoB.2 hours94.17% sensitivity and 100% specificity in the comparison reference.
Brand C Kit 2Sputum and respiratory tract samplesMTBC with rifampicin resistance via rpoB.~1.5 hours99.5% sensitivity and 95.5% specificity in the comparison reference.
Brand C Kit 3Sputum and respiratory tract samplesIsoniazid, ethionamide, fluoroquinolone, and second-line injectable drug markers including inhA, katG, fabG1, oxyR-ahpC, gyrA, gyrB, and eis.~1.5 hours64.7-93.1% sensitivity and 98.3-100% specificity in the comparison reference.
MGIT 960 CultureAll sample typesMTBC and NTM culture with all-drug phenotypic susceptibility context; co-infection and gene calls are not applicable.4-8 weeks70.25% sensitivity and 100% specificity in the comparison reference.

Performance values are shown as stated in the AITbiotech comparison reference; abNEX and MGIT values are based on a 201-sample comparison experiment, while Brand C kit values are based on manufacturer product data sheets.

Need help selecting the right workflow?

Genient can support assay selection, platform fit, validation planning, training, reporting workflow and downstream bioinformatics discussions.

Back To TB Portfolio arrow